Mass spectrometry and peptide-based vaccine development

I. G. Ovsyannikova, K. L. Johnson, Harold Robert (Bob) III Bergen, G. A. Poland

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The development of new vaccines against pathogens is an important part of infectious disease control. In the last decade, a variety of proteins giving rise to naturally processed pathogen-derived antigenic peptides, representing B-cell and T-cell epitopes, have been characterized. Numerous candidate vaccines consisting of synthetic peptides are being designed and evaluated, with encouraging results. In this context, the application of mass spectrometry based on the isolation and identification of pathogen-derived peptides from the human leukocyte antigen (HLA) molecules is a major focus of peptide-based vaccine development. Dramatic improvements have been made in mass spectrometer performance for peptide sequencing in terms of increased sensitivity, the ability to rapidly obtain data-directed tandem mass spectra, and the accuracy of mass measurement. This review focuses on the efforts to identify T-cell epitopes for viral and microbial pathogens for directed vaccine development.

Original languageEnglish (US)
Pages (from-to)644-652
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume82
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Subunit Vaccines
Mass Spectrometry
T-Lymphocyte Epitopes
Peptides
Vaccines
Synthetic Vaccines
HLA Antigens
Communicable Diseases
B-Lymphocytes
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mass spectrometry and peptide-based vaccine development. / Ovsyannikova, I. G.; Johnson, K. L.; Bergen, Harold Robert (Bob) III; Poland, G. A.

In: Clinical Pharmacology and Therapeutics, Vol. 82, No. 6, 12.2007, p. 644-652.

Research output: Contribution to journalArticle

Ovsyannikova, I. G. ; Johnson, K. L. ; Bergen, Harold Robert (Bob) III ; Poland, G. A. / Mass spectrometry and peptide-based vaccine development. In: Clinical Pharmacology and Therapeutics. 2007 ; Vol. 82, No. 6. pp. 644-652.
@article{1a6e5c49739144be9d1549c30ba52354,
title = "Mass spectrometry and peptide-based vaccine development",
abstract = "The development of new vaccines against pathogens is an important part of infectious disease control. In the last decade, a variety of proteins giving rise to naturally processed pathogen-derived antigenic peptides, representing B-cell and T-cell epitopes, have been characterized. Numerous candidate vaccines consisting of synthetic peptides are being designed and evaluated, with encouraging results. In this context, the application of mass spectrometry based on the isolation and identification of pathogen-derived peptides from the human leukocyte antigen (HLA) molecules is a major focus of peptide-based vaccine development. Dramatic improvements have been made in mass spectrometer performance for peptide sequencing in terms of increased sensitivity, the ability to rapidly obtain data-directed tandem mass spectra, and the accuracy of mass measurement. This review focuses on the efforts to identify T-cell epitopes for viral and microbial pathogens for directed vaccine development.",
author = "Ovsyannikova, {I. G.} and Johnson, {K. L.} and Bergen, {Harold Robert (Bob) III} and Poland, {G. A.}",
year = "2007",
month = "12",
doi = "10.1038/sj.clpt.6100389",
language = "English (US)",
volume = "82",
pages = "644--652",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Mass spectrometry and peptide-based vaccine development

AU - Ovsyannikova, I. G.

AU - Johnson, K. L.

AU - Bergen, Harold Robert (Bob) III

AU - Poland, G. A.

PY - 2007/12

Y1 - 2007/12

N2 - The development of new vaccines against pathogens is an important part of infectious disease control. In the last decade, a variety of proteins giving rise to naturally processed pathogen-derived antigenic peptides, representing B-cell and T-cell epitopes, have been characterized. Numerous candidate vaccines consisting of synthetic peptides are being designed and evaluated, with encouraging results. In this context, the application of mass spectrometry based on the isolation and identification of pathogen-derived peptides from the human leukocyte antigen (HLA) molecules is a major focus of peptide-based vaccine development. Dramatic improvements have been made in mass spectrometer performance for peptide sequencing in terms of increased sensitivity, the ability to rapidly obtain data-directed tandem mass spectra, and the accuracy of mass measurement. This review focuses on the efforts to identify T-cell epitopes for viral and microbial pathogens for directed vaccine development.

AB - The development of new vaccines against pathogens is an important part of infectious disease control. In the last decade, a variety of proteins giving rise to naturally processed pathogen-derived antigenic peptides, representing B-cell and T-cell epitopes, have been characterized. Numerous candidate vaccines consisting of synthetic peptides are being designed and evaluated, with encouraging results. In this context, the application of mass spectrometry based on the isolation and identification of pathogen-derived peptides from the human leukocyte antigen (HLA) molecules is a major focus of peptide-based vaccine development. Dramatic improvements have been made in mass spectrometer performance for peptide sequencing in terms of increased sensitivity, the ability to rapidly obtain data-directed tandem mass spectra, and the accuracy of mass measurement. This review focuses on the efforts to identify T-cell epitopes for viral and microbial pathogens for directed vaccine development.

UR - http://www.scopus.com/inward/record.url?scp=36148930239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148930239&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100389

DO - 10.1038/sj.clpt.6100389

M3 - Article

C2 - 17971823

AN - SCOPUS:36148930239

VL - 82

SP - 644

EP - 652

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -